Trials / Completed
CompletedNCT00165789
A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double-blind, two treatment, two group, parallel group study. Subjects will be randomized to one of two treatment groups (E2007 or Placebo) in a 3 to 1 ratio and receive treatment for a total of ten weeks (Days 1 to 70).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E2007 |
Timeline
- Start date
- 2005-09-01
- Primary completion
- 2006-02-01
- Completion
- 2006-09-01
- First posted
- 2005-09-14
- Last updated
- 2015-06-02
- Results posted
- 2015-06-02
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00165789. Inclusion in this directory is not an endorsement.